Biomarkers Correlation With Volemia
Launched by THERMOFISHER SCIENTIFIC BRAHMS BIOMARKERS FRANCE · May 16, 2013
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20 Cerebral Hemorrhage
- • 20 Head Injury
- • 20 post surgery non traumatic non neuro
- • 20 Polytrauma patients
- Exclusion Criteria:
- • Heart failure NYHA III or IV
- • Renal insufficiency creatinin clearance \< 30 ml/mn
- • age \< 18 Y
- • Pregnancy
About Thermofisher Scientific Brahms Biomarkers France
Thermo Fisher Scientific Brahms Biomarkers France is a leading clinical trial sponsor specializing in the development and commercialization of innovative biomarker solutions for diagnostic and therapeutic applications. With a strong focus on advancing personalized medicine, the organization leverages cutting-edge technology and extensive scientific expertise to enhance patient care through precise biomarker identification and validation. Committed to rigorous research standards, Thermo Fisher Scientific Brahms Biomarkers France plays a pivotal role in facilitating clinical studies that drive the discovery and implementation of novel diagnostic tools, ultimately contributing to improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Krémilin Bicêtre, Ile De France, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials